openPR Logo
Press release

Four weeks until SMi’s 21st Annual Superbugs & Superdrugs Conference 2019

02-19-2019 05:15 PM CET | Health & Medicine

Press release from: SMi Group

Superbugs & Superdrugs Conference 2019

Superbugs & Superdrugs Conference 2019

SMi Reports: Senior industry experts will gather in London to discuss the recent advances made in combating antibiotic resistance.

As the global threat of antimicrobial resistance continues to grow, the advances of modern medicines are at risk of being lost. Failure to act quickly means the spread of antibiotic-resistant bacteria could lead to increased mortality from normally minor injuries and benign infections.

For this reason, the Superbugs & Superdrugs conference, taking place on 18th-19th March 2019 in London, will gather leaders from pharmaceutical companies, academia and the wider scientific community together with regulatory agencies and public-private partnerships, to discuss the growing threat of antibiotic resistance.

The latest confirmed attendees for this year’s event include: ACS Dobfar SpA, Aelin Therapeutics, Akthelia Pharmaceuticals, AMR Centre, Destiny Pharma, Evotec UK, Fundeni Clinical Institute, LifeArc, Meiji Seika Pharma Co., MycoBiologics at University of Aberdeen, Phico Therapeutics, PSI CRO AG, University of Liverpool, University of North Texas Health Science Center, Walter Reed Army Institute of Research, Wollongong Hospital, and many more.

SMi are delighted to announce a new speaker, Dr Heather Fairhead, CEO of Phico Therapeutics, who will present on ‘SASProject: a novel first-in-class antibacterial technology’. Phico Therapeutics will also be sponsoring this year’s two-day conference.

In the run up to conference, SMi caught up with this year’s co-chair Lloyd Czaplewski, Director at Chemical Biology Ventures, to learn more about his role and perspectives on the state of the global threat of antibiotic resistance.

Exclusive snapshot of the interview below:

Q: What do you do in your day to day role and what perspective do you bring to the conference?

A: I work as CSO at Persica Pharmaceuticals Ltd, a clinical stage company, working on a novel treatment for Chronic Low Back Pain caused by bacterial infection of the spinal disc. In addition, I consult through Chemical Biology Ventures Ltd and work with Universities and funders e.g. Novo Repair Impact Fund.

Q: What role do you believe finding higher quality antifungal hits plays in leading the fight against AMR?

A: Better target validation and more tractable hits are both important, but the problem is multi-factorial. Look up what a 20-set Venn diagram and consider that the candidate is represented by one sector. That's the type of problem we are trying to solve.

Full speaker interview is available to download on the event website at http://www.superbugssuperdrugs.com/openpr

The two-day conference will host 19+ senior industry experts, giving detailed presentations on antimicrobial research development, novel antifungal agents, funding and regulations updates, as well as two half-day, post-conference interactive workshops on: “Understanding the complexity of the microbiome and how to navigate it” and “Understanding PK/PD in antimicrobial research”.

With only four weeks to go until the conference, interested parties can register online at http://www.superbugssuperdrugs.com/openpr

Superbugs & Superdrugs
Conference: 18th & 19th March 2019
Half-day post conference workshops: 20th March 2019
Holiday Inn Kensington Forum, London, UK

---- END ----

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

SMi Group Ltd
Registered & Head Office: SMi Group Ltd, India House, 45 Curlew Street, London, SE1 2ND
Contact Maria Mandic on mmandic@Smi-online.co.uk

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Four weeks until SMi’s 21st Annual Superbugs & Superdrugs Conference 2019 here

News-ID: 1600671 • Views: 504

More Releases from SMi Group

SMi Launches its 9th Annual Pre-Filled Syringes East Coast Conference
After nearly two years of virtual meetings the industry looks set to meet face to face and have some really important discussions and you are invited to join them. SMi’s 9th Annual Conference Pre-Filled Syringes East Coast Main Conference: April 25 - 26, 2022 | Workshops: April 27, 2022 Sheraton Boston Hotel, Boston, MA, USA www.pfsamericas.com/openPR1 Sponsors are: SCHOTT, ZEON Exhibitors: Owen Mumford Pharmaceutical Services, PHC Corporation, POLYPLASTICS- TOPAS, Weiss-Aug Group Device innovations, connected delivery
Only 6 weeks to go until The Transdermal and Microneedle Delivery Conference
SMi Reports: Time is running out to Register for SM’s inaugural conference: Transdermal and Microneedle Delivery will take place on 24th - 25th January 2022 SMi Group is proud to present the inaugural Transdermal and Microneedle Drug Delivery Conference, taking place on the 24th to 25th January 2022, in London, UK. The Conference will explore real world applications of microneedles in drug delivery and strategies for device design while engaging in
Only 6 weeks to go until the Pre-filled Syringes and Injectable Devices Conferen …
SMi Reports: Registration is open for SMi’s 14th Annual Conference and Exhibition taking place between 12th-13th January 2022 in London, UK. The pre-filled syringes industry is growing at an exponential rate with innovations in parenteral delivery device development to aid self-administration and deliver biologics, high concentration, and large-volume drug products. This year’s conference will explore the exciting advances in the combination product delivery space including insights into how the industry is
SMi Presents the 16th Annual Conference: Parallel Trade 2022
SMi Presents the 16th Annual Conference: Parallel Trade 2022 Conference Date: 21st – 22nd March 2022 Workshop date: 23rd March 2022 Website: www.parallel-trade.com/ Navigating the challenges and legal landscapes of parallel trade SMi presents its 16th annual Parallel Trade conference on the 21st and the 22nd March 2022. As the only parallel trade conference in Europe, this event provides the perfect platform for industry experts from both sides of the coin to come together

All 5 Releases


More Releases for Superbugs

Interview with Martin Everett speaker at SMi's Superbugs & Superdrugs Conference
SMi Reports: An Interview with Martin Everett, Chief Scientific Officer, at Antabio, who will be speaking at SMi's highly anticipated 22nd Annual Superbugs & Superdrugs Conference on the 30th and 31st March 2020 in London. This year's global focused two-day conference pharmaceutical is for industry professionals looking to gain an in-depth knowledge of the scientific, economic, and regulatory challenges facing the critical global issue of antibiotic resistance. For interested individuals to attend
Registration Officially Opens for the 21st Annual Superbugs & Superdrugs Confere …
As the global threat of antimicrobial resistance continues to grow, the advances of modern medicine are at risk of being lost. Failure to act quickly means the spread of antibiotic-resistant bacteria could lead to increased mortality from normally minor injuries and benign infections. SMi’s highly anticipated Superbugs & Superdrugs conference is set to return to London, UK for its 21st year running, on the 18th & 19th March 2019 (http://www.superbugssuperdrugs.com/openpr). This
W. J. Wiess and A.S. Lynch invitation to SMi’s Superbugs & Superdrugs USA Conf …
SMi Group reports: William J. Weiss - University of North Texas Health Science Center and Anthony Simon Lynch - Janssen supporting SMi's Superbugs & Superdrugs USA Conference, which is due to take place this November in New Jersey William and Anthony are chairing SMi's Superbugs & Superdrugs USA Conference and encourage all involved in AMR to join experts from multiple disciplines, in the field of infectious disease representing research, regulatory, funding,
Superbugs & Superdrugs USA Conference returns to New Jersey this November
SMi Group reports: agenda released for 3rd annual Superbugs & Superdrugs USA conference Building on almost two decades worth of expertise in fighting the growing threat of antimicrobial resistance (AMR), SMi Group is pleased to announce the release of the official agenda for the 3rd annual Superbugs & Superdrugs USA Conference, which is due to take place in Iselin, New Jersey on November 12 - 13, 2018. Antimicrobial resistance, leading to the
Antibiotic Drug Experts + Senior Industry Leaders set to Gather at Superbugs USA
SMi Group will open doors in 3 weeks to host the next annual USA Superbugs summit when it returns to Iselin, New Jersey on Nov 13th – 14th. http://www.superbugs-usa.com/opr Following over two decades of expertise in Europe, the USA show will gather senior industry experts to delve deeper into core issues surrounding government funding and initiatives, breakthroughs in drug discovery, strategies to strengthen the antibiotic pipeline and resistance prevention. Highlights will include
Motif Biosciences Unveil Novel Solutions for the Treatment Deadly Superbugs
SMi Group will welcome the expertise of David Huang when he presents exclusive updates on Iclaprim, a novel diaminopyrimidine, for the treatment of serious gram- positive infections, at Superbugs & Superdrugs USA this fall. The talk will explore how Iclaprim addresses an unmet medical need in hospitalized patients with serious and life-threatening infections including MRSA. With over 15 years of clinical, academic, industry, and research experience in medicine and in the